Donate

2017

March 12, 2019

A subcutaneous, bi-specific antibody therapy becomes commercially available to those with hemophilia A and inhibitors. This product gets approval for hemophilia A patients a year later.


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.